Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | CTRC | Q99895 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747735 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL12119582 | 0.87 | ALDH1A1 (0.77) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL1023519 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1USP2TSHR | |
| SCHEMBL13783795 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1USP2TSHR | |
| SCHEMBL12372537 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1USP2TSHR | |
| SCHEMBL7382903 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CA1CA2CA9KMT2A | |
| SCHEMBL7382899 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CA1CA2CA9KMT2A | |
| SCHEMBL3236740 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL8383162 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1USP2TSHR | |
| SCHEMBL7829113 | 0.81 | ALDH1A1 (0.93) | ALDH1A1KMT2AMEN1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656642-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | GAN & LEE PHARM CO., LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2025026283-A1 | COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF | 甘李药业股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-4471033-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024156294-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | 甘李药业股份有限公司 | 2024-08-02 | — | — | WO | disclosed |
| WO-2023143589-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | ALDH1A1 3364/4885CA12 1839/4885CA1 691/4885 |
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | ALDH1A1 145/4885CA12 4489/4885CA1 2991/4885 |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | ALDH1A1 2742/4885CA12 3408/4885CA1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.